Search for: "Johnson & Johnson Inc" Results 421 - 440 of 4,525
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
21 Oct 2021, 8:37 am by Samuel Bray
All.BondFund, Inc., 527 U.S.308 (1999), the State argues for limiting equitable actions to the exact claims available at common law. [read post]
15 Oct 2021, 12:33 pm by Silver Law Group
He was previously employed with Merrill Lynch, Pierce, Fenner & Smith Incorporated (CRD#:7691), also of Duluth, MN, Wells Fargo Investments, LLC (CRD#:10582) of Grand Rapids, MN, and Miller Johnson Steichen Kinnard, Inc. [read post]
8 Oct 2021, 6:00 am
Parker, Tracey-Lee Brown, and Gregory Johnson, PricewaterhouseCoopers LLP, on Sunday, October 3, 2021 Tags: Audit committee, Boards of Directors, Climate change, Environmental disclosure, ESG, Oversight, Securities regulation, Stakeholders, Sustainability Cybersecurity and Disclosures Posted by Paul Ferrillo (Seyfarth Shaw LLP), Bob Zukis (USC Marshall School of Business), and George Platsis (Booz Allen Hamilton),… [read post]
8 Oct 2021, 3:47 am by Andrew Lavoott Bluestone
Bill Birds, Inc. v Stein Law Firm, P.C., 35 NY3d 173, 178; see generally CDR Créances S.A.S. v Cohen, 23 NY3d 307, 315; ), no such cause of action has been pleaded in this case (see DeMartino v Abrams, Fensterman, Fensterman, Eisman, Formato, Ferrara & Wolf, LLP, 189 AD3d 774, 775). [read post]
6 Oct 2021, 1:08 pm by Rebecca Tushnet
Take-Two Interactive Software, Inc., 97 N.E.3d 389 (N.Y. 2018). [read post]
21 Sep 2021, 1:25 pm by Tom Lamb
Our law firm is investigating cases for patients who have suffered the Padcev skin side effects Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) as possible drug injury lawsuits to be filed against Astellas Pharma US, Inc., the manufacturer of Padcev. [read post]
18 Sep 2021, 8:45 pm by Patent Docs
The program will consist of two panels: • Panel I -- Current Topics in the Federal Circuit’s Law of Written Description and Enablement -- John Josef Molenda of Steptoe & Johnson LLP will moderate a panel consisting of Larry Coury of Regeneron Pharmaceuticals, Inc.; Henry Hadad of Bristol-Myers Squibb; Joshua Rosenkranz of Orrick, Herrington & Sutcliffe LLP; and John Whealan of The George Washington... [read post]